BiotechTube

E7046

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumors

Conditions

Tumors

Trial Timeline

Jul 30, 2015 → Feb 27, 2018

NCT ID
NCT02540291

About E7046

E7046 is a phase 1 stage product being developed by Eisai for Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT02540291. Target conditions include Tumors.

What happened to similar drugs?

8 of 20 similar drugs in Tumors were approved

Approved (8) Terminated (4) Active (8)
✅Everolimus (RAD001)NovartisApproved
✅everolimusNovartisApproved
✅Imatinib MesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02540291Phase 1Terminated

Competing Products

20 competing products in Tumors

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
E7050EisaiPhase 1
29
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
CixutumumabEli LillyPhase 1
29
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27
ZN-c3 + Bevacizumab + PembrolizumabZentalis PharmaceuticalsPhase 1
11
IMC-18F1Eli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
ACR-2316Acrivon TherapeuticsPhase 1
26
LY2875358 + Erlotinib + GefitinibEli LillyPhase 1
29
Tomivosertib (eFT-508)eFFECTOR TherapeuticsPhase 2
25
SPYK04Chugai PharmaceuticalPhase 1
33
AUBE00 + CetuximabChugai PharmaceuticalPhase 1
36
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
ERY974Chugai PharmaceuticalPhase 1
29
DS3610aDaiichi SankyoPhase 1
36
Tivantinib (ARQ 197) Capsule + Tivantinib (ARQ 197) Tablet + Tivantinib (ARQ 197) Capsule D, oralDaiichi SankyoPhase 1
29